Compare Abeona Therapeutics Inc (ABEO) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Alphabet Inc Class A — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Alphabet Inc Class A trades at $361.35 (market cap $4.46T). The key difference: Alphabet Inc Class A is far larger — about 11946.9× Abeona Therapeutics Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GOOGL | |
|---|---|---|
Market Cap | $373.32M | $4.46T |
Sector | Health | Media |
52-Week High | $7.23 | $402.62 |
52-Week Low | $4.17 | $174.36 |
Enterprise Value | $228.22M | $4.42T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Alphabet (GOOGL) trades at $360.42, down 1.65% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $402.84B and net income of $132.17B, achieving 37.92% net margins. Recent earnings beats and a $0.22 dividend payment in June 2026 highlight operational strength, while analyst consensus remains overwhelmingly positive with 85% buy ratings.
Alphabet presents a compelling investment case with consistent earnings outperformance and AI-driven growth potential, though investors should monitor regulatory challenges and competitive pressures. The stock trades at a 28 P/E ratio with a $431.35 consensus price target representing 20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
